🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. Rusfertide 45mg, Rusfertide 60mg, Rusfertide 30mg, Rusfertide 10mg, Rusfertide 20mg, Placebo to Match PTG-300 for Injection. Formulation (lyophilized powder) is based upon that of PTG-300 for Injection, with the drug substance omitted.

    Protagonist Therapeutics, Inc

    Polycythemia Vera

    phase 3 small molecule active

    1 trial

  2. Ruxolitinib (INCB018424) cream, Ruxolitinib (INCB018424) cream, Vehicle (placebo) cream

    Incyte

    Vitiligo

    phase 3 small molecule active

    1 trial

  3. Ruxolitinib (INCB018424) cream, Vehicle cream (same formulation of cream as the test product but without active substance and the phosphoric acid)

    Incyte

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  4. Rybelsus 3 mg tablets, Rybelsus 14 mg tablets, Placebo (semaglutide) tablets, Rybelsus 7 mg tablets

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  5. Rybelsus 7 mg tablets, Placebo (semaglutide) tablet, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  6. Rybelsus 7 mg tablets, Placebo (semaglutide) tablets, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  7. Ryzodeg 100 units/mL FlexTouch solution for injection in pre-filled pen, IcoSema 700 U/mL + 2 mg/mL PDS290

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  8. S-1 therapy

    The First People's Hospital of Lianyungang

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule active

    1 trial

  9. S-217622

    Shionogi B.V.

    SARS-CoV-2 Infection

    phase 3 small molecule completed

    1 trial

  10. S-268019-b

    Shionogi B.V.

    SARS-CoV-2

    phase 3 small molecule completed

    1 trial

  11. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Huntington's Disease

    phase 3 small molecule terminated

    2 trials

  12. SALBUTAMOL , Tozorakimab, Tozorakimab-placebo

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  13. SALINE, Fazirsiran

    Takeda

    Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

    phase 3 small molecule active

    1 trial

  14. SALINE, GEMCITABINE, GEMCITABINE, Quemliclustat, GEMCITABINE, PACLITAXEL ALBUMIN-BOUND

    Arcus Biosciences

    Pancreatic cancer, Metastatic Pancreatic ductal adenocarcinoma (mPDAC), Pancreatic ductal adenocarcinoma (PDAC)

    phase 3 small molecule active

    1 trial

  15. SAMYR 400 mg compresse gastroresistenti, Samyr placebo (same excipient as SAMYR)

    Mylan Pharma UK

    Major Depression Disorder

    phase 3 small molecule active

    1 trial

  16. SANDOSTATIN LAR 10 mg powder and solvent for suspension for injection, LysaKare 25 g/25 g solution for infusion, SANDOSTATIN LAR 20 mg powder and solvent for suspension for injection, SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Lutathera 370 MBq/mL solution for infusion

    Advanced Accelerator Applications

    Patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs

    phase 3 small molecule active

    1 trial

  17. SAR153191 (REGN88)

    Regeneron UK Limited

    Rheumatoid Arthritis

    phase 3 small molecule completed

    2 trials

  18. SAR439774

    Genzyme Europe B.V.

    Hemophilia

    phase 3 small molecule active

    1 trial

  19. SAR439774, SAR439774

    Sanofi-aventis Healthcare Pty Ltd

    Hemophilia

    phase 3 small molecule active

    1 trial

  20. SARCLISA 20mg/mL concentrate for solution for infusion., Iclusig 15 mg film-coated tablets, SARCLISA 20mg/mL concentrate for solution for infusion., BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion.

    Pari Pharma GmbH

    Patients aged 18-65 years old with newly diagnosed previously untreated ALL or T-LL.

    phase 3 small molecule active

    1 trial

  21. SARS-CoV-2 Vaccine (Vero Cell), Inactivated

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19 Pneumonia

    phase 3 mab completed

    1 trial

  22. SARS-CoV-2 inactivated vaccine

    Sinovac Research and Development Co.,

    Covid19

    phase 3 mab completed

    1 trial

  23. SARS-CoV-2 mRNA Vaccine

    Biotech Pharmaceutical Co.,

    COVID-19

    phase 3 mab active

    1 trial

  24. SB-497115-GR 12.5mg

    GlaxoSmithKline

    Chronic Idiopathic Thrombocytopenic Purpura

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources